The global RNA-based therapeutics market size was estimated to be USD 13.83 billion in 2023 and is expected to reach USD 25.47 billion by 2034 with a CAGR of 5.71% during the forecast period 2024-2034. The rising prevalence of chronic diseases, advancements in RNA technologies, growing adoption of personalized medicine, growing investment and funding, and collaborations between pharmaceutical companies will drive the market growth.
The increased prevalence of chronic illnesses such as cancer, cardiovascular disease, and neurological disorders drives the need for novel therapeutic alternatives. RNA therapeutics provides prospective pathways for targeted and customized medicines, which has resulted in major investment and research in this sector. For instance, in December 2023, Pfizer and BioNTech announce the filing to the European Medicines Agency (EMA) of a marketing authorization application (MAA) for a bivalent COVID-19 booster vaccine targeting the Omicron BA.4/BA.5 subvariants.
By drug class, the antisense oligonucleotides segment accounted for the highest revenue-grossing segment in the global RNA-based therapeutics market in 2023 owing to the innovative advancements in nucleic acid technology, which enabled the development of highly specific and efficient antisense oligonucleotides (ASOs). These ASOs demonstrated remarkable therapeutic potential by selectively targeting and modulating the expression of disease-associated genes, leading to increased adoption in the treatment of various genetic disorders, neurodegenerative diseases, and other conditions. For instance, in November 2023, Moderna files a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for mRNA-1278, a tailored cancer vaccine. Additionally, the mRNA therapeutics segment is predicted to grow at the fastest CAGR during the forecast period owing to the revolutionary success and widespread acceptance of mRNA-based vaccines, particularly exemplified by the remarkable efficacy demonstrated in combating infectious diseases such as COVID-19. This breakthrough has significantly boosted confidence in mRNA technology, fostering increased investment, research, and development across diverse therapeutic areas.
By therapeutic area, the oncology segment accounted for the highest revenue-grossing segment in the global RNA-based therapeutics market in 2023 owing to the robust clinical efficacy demonstrated by RNA-based therapeutics in addressing various oncological indications. The targeted nature of RNA therapies, such as mRNA vaccines and antisense oligonucleotides, has showcased promising results in the treatment of different cancers, fostering increased adoption and investment in oncology-focused RNA research and development. For instance, Ionis and AstraZeneca announce the start of a Phase 2 trial of IONIS-TTRrx, an experimental RNA antisense medication for the treatment of hereditary transthyretin amyloidosis (hATTR), in October 2023. Additionally, the genetic disorders segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of RNA-based therapeutics as a promising and targeted approach for addressing a spectrum of genetic disorders. Advances in understanding the genetic basis of various hereditary conditions, coupled with the development of innovative RNA technologies such as antisense oligonucleotides and RNA editing tools, have fueled optimism in the treatment of genetic disorders.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global RNA-based therapeutics market in 2023 owing to the increased adoption of RNA-based therapeutics for the treatment of a diverse range of diseases and the expanding integration of these innovative therapies into standard medical practices within hospital and clinic settings. For instance, Arrowhead announced the first participant in a Phase 1b/2a study of ARO-AAT, an experimental RNA interference (RNAi) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD), in November 2023. Additionally, the research institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating focus on cutting-edge scientific discoveries and the pivotal role research institutes play in advancing the understanding and development of RNA-based therapeutics.
North American region is anticipated for the highest revenue share during the forecast period owing to the robust infrastructure for biopharmaceutical research and development, a well-established regulatory framework, and a high level of investment in healthcare innovation. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of genetic disorders and infectious diseases, coupled with increasing investments in healthcare infrastructure, research, and development. For instance, in November 2023, Translate Bio announces a strategic agreement with Novartis to research and market mRNA therapies for inflammatory disorders. This partnership takes use of their complementary capabilities in mRNA technology and inflammatory disease understanding.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The increased prevalence of chronic illnesses such as cancer, cardiovascular disease, and neurological disorders drives the need for novel therapeutic alternatives. RNA therapeutics provides prospective pathways for targeted and customized medicines, which has resulted in major investment and research in this sector. For instance, in December 2023, Pfizer and BioNTech announce the filing to the European Medicines Agency (EMA) of a marketing authorization application (MAA) for a bivalent COVID-19 booster vaccine targeting the Omicron BA.4/BA.5 subvariants.
By drug class, the antisense oligonucleotides segment accounted for the highest revenue-grossing segment in the global RNA-based therapeutics market in 2023 owing to the innovative advancements in nucleic acid technology, which enabled the development of highly specific and efficient antisense oligonucleotides (ASOs). These ASOs demonstrated remarkable therapeutic potential by selectively targeting and modulating the expression of disease-associated genes, leading to increased adoption in the treatment of various genetic disorders, neurodegenerative diseases, and other conditions. For instance, in November 2023, Moderna files a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for mRNA-1278, a tailored cancer vaccine. Additionally, the mRNA therapeutics segment is predicted to grow at the fastest CAGR during the forecast period owing to the revolutionary success and widespread acceptance of mRNA-based vaccines, particularly exemplified by the remarkable efficacy demonstrated in combating infectious diseases such as COVID-19. This breakthrough has significantly boosted confidence in mRNA technology, fostering increased investment, research, and development across diverse therapeutic areas.
By therapeutic area, the oncology segment accounted for the highest revenue-grossing segment in the global RNA-based therapeutics market in 2023 owing to the robust clinical efficacy demonstrated by RNA-based therapeutics in addressing various oncological indications. The targeted nature of RNA therapies, such as mRNA vaccines and antisense oligonucleotides, has showcased promising results in the treatment of different cancers, fostering increased adoption and investment in oncology-focused RNA research and development. For instance, Ionis and AstraZeneca announce the start of a Phase 2 trial of IONIS-TTRrx, an experimental RNA antisense medication for the treatment of hereditary transthyretin amyloidosis (hATTR), in October 2023. Additionally, the genetic disorders segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of RNA-based therapeutics as a promising and targeted approach for addressing a spectrum of genetic disorders. Advances in understanding the genetic basis of various hereditary conditions, coupled with the development of innovative RNA technologies such as antisense oligonucleotides and RNA editing tools, have fueled optimism in the treatment of genetic disorders.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global RNA-based therapeutics market in 2023 owing to the increased adoption of RNA-based therapeutics for the treatment of a diverse range of diseases and the expanding integration of these innovative therapies into standard medical practices within hospital and clinic settings. For instance, Arrowhead announced the first participant in a Phase 1b/2a study of ARO-AAT, an experimental RNA interference (RNAi) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD), in November 2023. Additionally, the research institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating focus on cutting-edge scientific discoveries and the pivotal role research institutes play in advancing the understanding and development of RNA-based therapeutics.
North American region is anticipated for the highest revenue share during the forecast period owing to the robust infrastructure for biopharmaceutical research and development, a well-established regulatory framework, and a high level of investment in healthcare innovation. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of genetic disorders and infectious diseases, coupled with increasing investments in healthcare infrastructure, research, and development. For instance, in November 2023, Translate Bio announces a strategic agreement with Novartis to research and market mRNA therapies for inflammatory disorders. This partnership takes use of their complementary capabilities in mRNA technology and inflammatory disease understanding.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Class, Therapeutic Area, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: RNA-based Therapeutics Market Report 2023 - 2034
RNA-based Therapeutics Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- RNA Aptamers
- siRNA
- Antisense Oligonucleotides
- mRNA
RNA-based Therapeutics Market Analysis & Forecast by Therapeutic Area 2023 - 2034 (Revenue USD Bn)
- Oncology
- Genetic Disorders
- Ophthalmology
- Hematological Disorders
RNA-based Therapeutics Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Research Institutes
- Hospitals & Clinics
- Others
RNA-based Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. RNA-based Therapeutics Market: Drug Class Estimates & Trend Analysis
8. RNA-based Therapeutics Market: Therapeutic Area Estimates & Trend Analysis
9. RNA-based Therapeutics Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America RNA-based Therapeutics Market
12. Europe Global RNA-based Therapeutics Market
13. Asia Pacific Global RNA-based Therapeutics Market
14. Latin America Global RNA-based Therapeutics Market
15. MEA Global RNA-based Therapeutics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Roche Holdings AG
- Dicerna Pharmaceuticals Inc.
- Translate Bio Inc.
- CureVac N.V.
- Regulus Therapeutics Inc.
- Sarepta Therapeutics Inc.
- BioNTech SE
- miRagen Therapeutics Inc.
- Dynavax Technologies Corporation
- Quark Pharmaceuticals Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 13.83 Billion |
| Forecasted Market Value ( USD | $ 25.47 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
